Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BG129
- Development stage
- Preclinical
- Lead developer
- Merrimack Pharmaceuticals
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
BG129 is a novel small molecule inhibitor of Ataxia telangiectasia and Rad3-related (ATR) protein kinase, a key regulator of the DNA damage response (DDR) pathway. Developed by Merrimack Pharmaceuticals, BG129 is designed to be used in combination with DNA-damaging agents, such as carboplatin, gemcitabine, or irinotecan, to enhance their anti-tumor activity by blocking DNA repair mechanisms in cancer cells. To address the rapid clearance observed with early ATR inhibitors, BG129 was formulated into nano-liposomes (nLs-BG129). This formulation significantly improves the pharmacokinetic profile, providing prolonged clearance and enhanced efficacy in preclinical models of ovarian and lung cancers.
- Other names
- nLs-BG129nLs-BG-129nLs-BG 129
Beyond the preview
Go deeper on BG129.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BG129.